SOHO Brazil

 

SOHO Brazil 2024
Avatar

The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML

By SOHO Brazil 2024 FEATURING Jeffrey Lancet
By SOHO Brazil 2024 FEATURING Jeffrey Lancet
116 views
July 11, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
SOHO Brazil 2024
18:13
SOHO Brazil 2024

SOHO Brazil 2024: Treatment of Primary CNS Lymphoma

Feat. A. Alencar
20:49
SOHO Brazil 2024

Summary of Recent Updates in Advanced Hodgkin Lymphoma

Feat. C. Moskowitz
27:26
SOHO Brazil 2024

Where I Use Azacitidine and Venetoclax in AML: Present and Future

Feat. J. Lancet
22:29
SOHO Brazil 2024

1L Therapy in CLL: What Are the Best Options?

Feat. J. Burger
13:22
SOHO Brazil 2024

Managing Infectious Complications With Bispecific and CAR-T Therapy …

Feat. N. S. Raje
20:23
SOHO Brazil 2024

When to Consider Bispecific and CAR-T Therapy in MM

Feat. N. S. Raje
16:44
SOHO Brazil 2024

Frontline MM: Are Four Better Than Three?

Feat. N. S. Raje
19:14
SOHO Brazil 2024

FL: How Do I Deal With Relapse?

Feat. B. Kahl
15:25
SOHO Brazil 2024

To 2L and Beyond: Treatment Options in R/R MCL

Feat. T. Phillips
20:01
SOHO Brazil 2024

FL Updates: Is There a Standard 1L Treatment?

Feat. B. Kahl
21:12
SOHO Brazil 2024

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

Feat. J. Burger
18:29
SOHO Brazil 2024

Single vs. Multiple Agents in 2L Therapy for CLL

Feat. J. Burger
19:21
SOHO Brazil 2024

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

Feat. J. Lancet
17:01
SOHO Brazil 2024

Are We Closer to Conquering HR-MDS?

Feat. R. Komrokji
21:26
SOHO Brazil 2024

Therapies on the Horizon in LR- and HR-MDS

Feat. R. Komrokji
20:25
SOHO Brazil 2024

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …

Feat. A. Zelenetz
14:17
SOHO Brazil 2024

DLBCL Pts Ineligible for CAR-T Therapy: Do They Exist and How Do We …

Feat. A. Zelenetz
15:02
SOHO Brazil 2024

Summary of Updates in R/R DLBCL Treatment

Feat. A. Alencar
22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
18:06
SOHO Brazil 2024

Summary of Recent Updates in R/R HL

Feat. C. Moskowitz
19:13
SOHO Brazil 2024

Summary of Recent Updates on LR-MDS Management

Feat. R. Komrokji
19:52
SOHO Brazil 2024

How Are Targeted Therapies Redefining the Treatment Paradigm in ALL …

Feat. J. Burger
19:07
SOHO Brazil 2024

Early Stage HL: Can Radiation Therapy Be Eliminated?

Feat. C. Moskowitz
38:54
SOHO Brazil 2024

PNH: Summary of Latest Advancements and Case Discussion

Feat. B. Fattizzo
20:33
SOHO Brazil 2024

The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML

Feat. J. Lancet
17:30
SOHO Brazil 2024

Making Sense of 1L Treatment Options in MCL

Feat. T. Phillips